A recent study has demonstrated that using gene therapy to correct half of the faulty heart muscle cells in a mouse model of Friedreich's ataxia completely reverses cardiomyopathy. Read more
Ataxia UK is on the steering committee of these two Global Ataxia Schemes, which hope to advance clinical research into ataxia on a worldwide scale. Read more
Ataxia UK uses Researchfish to analyse the impact of Ataxia UK-funded research. This report summarises data from 39 grants, awarded between 2009 and 2018. Read more
Leading gene therapy company uniQure have announced preclinical data on its gene therapy candidate, AMT-150, for the treatment of Spinocerebellar Ataxia 3 (SCA3). Read more
Professor Giunti and her team have identified a potential biomarker for FA by investigating the eye problems commonly found in patients. Read more
A mutation in gene found to be responsible for CANVAS, a specific form of late onset ataxia, is likely to also be responsible for forms of late onset ataxia with unknown causes. Read more
A group of researchers from Germany have found that real-time audio bio-feedback improves stability in degenerative cerebellar ataxia. Read more
A recently published study has demonstrated that intensive home-based speech therapy can improve dysarthria (difficulty speaking) in autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Read more
The AMRC Impact Report highlights the concrete ways that medical research charities make a difference to people and society through the research they fund Read more
The 'New Modalities Ecosystem’, launched in 2018 by the Finnish pharmaceutical company Orion, aims to exploit Finnish expertise to deliver new treatments and technologies for rare diseases. Read more
A recent study investigating the effect of investigating the effect of physiotherapy on patients with spinocerebellar ataxia type 7 (SCA7) has found that it to significantly improve symptoms. Read more
Ataxia UK's Head of Research Julie Greenfield reports on the 2018 Euro-ataxia annual conference held in Frankfurt. Read more
The ongoing European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) study, part-funded by Ataxia UK has released a report evaluating the clinical variability in Friedreich’s ataxia (FA) symptoms. Read more
Experiments in the laboratory using skin cells taken from people with Friedreich’s ataxia have shown that these cells may be more susceptible to damage caused by certain sun rays. Read more
Ataxia UK has been talking with Minoryx Therapeutics, a company focusing on developing new drugs for rare conditions, and we are delighted with this new trial being announced. Read more
We are delighted that on 20 February 2019 the Ataxia UK Medical Guidelines were published in the Orphanet Journal of Rare Diseases. Read more
A study has found that a rapid, non-invasive eye exam could potentially be used as a tool for assessing Friedreich's ataxia patients and as a biomarker in clinical trials. Read more
Experiments performed in mice and in cells taken from Friedreich's ataxia (FA) patients reveal a protein called 'GRP75' might be an effective future treatment approach. Read more
The results of the patient communications survey conducted at the 2018 Ataxia UK conference were presented in London by Ataxia UK partners Costello Medical. Read more
Study finds anti-viral drug leads to decrease in frataxin levels and may be a potential future candidate for treating Friedreich's ataxia (FA). Read more